Celyad Oncology SA (EBR:CYAD)

Market Cap	13.92M -30.4%
Revenue (ttm)	21.00K -88.7%
Net Income	830.00K
EPS	0.02
Shares Out	44.76M
PE Ratio	17.28
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,901
Average Volume	14,604
Open	0.3110
Previous Close	0.3190
Day's Range	0.3110 - 0.3190
52-Week Range	0.1600 - 0.6500
Beta	1.22
RSI	46.49
Earnings Date	Sep 23, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD